Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7280 DDI Study in Healthy Subjects
NCT06949124Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR7280 in endometriosis, Uterine Fibroids (UF) and infertility, sponsored by Hengrui. Primary endpoints: Maximum concentration up to 29 days, Area under the curve from time 0 to infinity up to 29 days and 1 more. Started Apr 2025; status: completed.
02
Drugs
SHR7280
03
Conditions
endometriosisUterine Fibroids (UF)infertility
Beyond the preview
Go deeper on NCT06949124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949124.